A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
Status:
Completed
Trial end date:
2018-07-25
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, 3 treatment, 3-period, 6-sequence, crossover study
conducted at a single study center to characterize the relative bioavailability of
relacorilant administered as 3×100-mg softgel capsules (Treatment A), 3×100 mg hard-shell
capsules (Treatment B), and 6×50-mg hard shell capsules (Treatment C/reference) in healthy,
fasted, adult subjects.
Eligible subjects will participate in 3 treatment periods. During each treatment period,
subjects will receive a single 300-mg relacorilant dose. An equal number of subjects will be
randomized to each of 6 sequences.